Molecular and Epigenetic Aspects of Opioid Receptors in Drug Addiction and Pain Management in Sport
暂无分享,去创建一个
[1] B. Roth,et al. Structures of the entire human opioid receptor family , 2023, Cell.
[2] Handong Ouyang,et al. CircNf1-mediated CXCL12 expression in the spinal cord contributes to morphine analgesic tolerance , 2022, Brain, Behavior, and Immunity.
[3] N. Mercuri,et al. Morpho‐Functional Changes of Nigral Dopamine Neurons in an α‐Synuclein Model of Parkinson's Disease , 2022, Movement disorders : official journal of the Movement Disorder Society.
[4] A. Viggiano,et al. Neuroinflammation: molecular mechanisms and therapeutic perspectives. , 2022, Central nervous system agents in medicinal chemistry.
[5] T. Robbins,et al. Multi-omics study reveals associations among neurotransmitter, extracellular vesicle-derived microRNA and psychiatric comorbidities during heroin and methamphetamine withdrawal. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[6] Jingwei Tian,et al. MicroRNAs in drug addiction: Current status and future perspectives. , 2022, Pharmacology & therapeutics.
[7] Ling-Ling Chen,et al. Circular RNAs: Characterization, cellular roles, and applications , 2022, Cell.
[8] X. Li,et al. CircTmeff-1 in the nucleus accumbens regulates the reconsolidation of cocaine-associated memory , 2022, Brain Research Bulletin.
[9] I. Pronina,et al. Circulating MicroRNAs as a New Class of Biomarkers of Physiological Reactions of the Organism to the Intake of Dietary Supplements and Drugs. , 2022, MicroRNA.
[10] N. Mercuri,et al. Pathophysiological Features of Nigral Dopaminergic Neurons in Animal Models of Parkinson’s Disease , 2022, International journal of molecular sciences.
[11] M. Wimmer,et al. microRNA expression levels in the nucleus accumbens correlate with morphine‐taking but not morphine‐seeking behaviour in male rats , 2022, The European journal of neuroscience.
[12] H. Pan,et al. Epigenetic Mechanisms of Neural Plasticity in Chronic Neuropathic Pain. , 2022, ACS chemical neuroscience.
[13] K. Dąbrowski,et al. Heroin Regulates Orbitofrontal Circular RNAs , 2022, International journal of molecular sciences.
[14] Hailei Yu,et al. Roles of miR-592-3p and Its Target Gene, TMEFF1, in the Nucleus Accumbens During Incubation of Morphine Craving , 2022, The international journal of neuropsychopharmacology.
[15] Y. Olsen. What Is Addiction? History, Terminology, and Core Concepts. , 2022, The Medical clinics of North America.
[16] Rajesh Raju,et al. Opioid receptors signaling network , 2021, Journal of Cell Communication and Signaling.
[17] Lieliang Zhang,et al. Long Non-coding RNAs and Circular RNAs: Insights Into Microglia and Astrocyte Mediated Neurological Diseases , 2021, Frontiers in Molecular Neuroscience.
[18] Cailian Cui,et al. MicroRNA‐132 is involved in morphine dependence via modifying the structural plasticity of the dentate gyrus neurons in rats , 2021, Addiction biology.
[19] S. Bradburn,et al. Differential expression of H19, BC1, MIAT1, and MALAT1 long non-coding RNAs within key brain reward regions after repeated morphine treatment , 2021, Behavioural Brain Research.
[20] E. Sohn. Treatment of neuropathic pain , 2021, Journal of the Korean Medical Association.
[21] K. Iczkowski,et al. Peripheral antinociceptive effects of a bifunctional μ and δ opioid receptor ligand in rat model of inflammatory bladder pain , 2021, Neuropharmacology.
[22] P. Vivekanandan,et al. Biogenesis, characterization, and functions of mirtrons , 2021, Wiley interdisciplinary reviews. RNA.
[23] T. Zandonai,et al. Codeine and Tramadol Use in Athletes: A Potential for Abuse , 2021, Frontiers in Pharmacology.
[24] B. Cong,et al. The role of circTmeff-1 in incubation of context-induced morphine craving. , 2021, Pharmacological research.
[25] D. Fischer,et al. CXCR4/CXCL12-mediated entrapment of axons at the injury site compromises optic nerve regeneration , 2021, Proceedings of the National Academy of Sciences.
[26] J. Cadet,et al. Epigenetics of addiction , 2021, Neurochemistry International.
[27] B. Tai,et al. The NIDA clinical trials network: evolving, expanding, and addressing the opioid epidemic , 2021, Addiction Science & Clinical Practice.
[28] C. Mortali,et al. Opioid epidemic spread from Northern and Eastern Europe to Mediterranean Area. , 2021, La Clinica terapeutica.
[29] M. Lai,et al. Role of nucleus accumbens microRNA-181a and MeCP2 in incubation of heroin craving in male rats , 2021, Psychopharmacology.
[30] Yusheng Yao,et al. Efficacy of systemic lidocaine on postoperative quality of recovery and analgesia after video-assisted thoracic surgery: A randomized controlled trial. , 2021, Journal of clinical anesthesia.
[31] H. Loh,et al. Kappa opioid receptor controls neural stem cell differentiation via a miR‐7a/Pax6 dependent pathway , 2021, Stem cells.
[32] K. Sangkuhl,et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy , 2021, Clinical pharmacology and therapeutics.
[33] F. Mazzeo,et al. Data investigation on the performance-enhancing drugs spread in Italy among young athletes: Prevention trough education and the fight against doping in sport , 2021 .
[34] A. Dmitriev,et al. LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms , 2020, International journal of molecular sciences.
[35] E. Oleson,et al. Buprenorphine is a weak dopamine releaser relative to heroin, but its pretreatment attenuates heroin‐evoked dopamine release in rats , 2020, Neuropsychopharmacology reports.
[36] Xiaoding Xu,et al. Non-coding RNAs: the new central dogma of cancer biology , 2020, Science China Life Sciences.
[37] T. Leroux,et al. Opioid Use in Athletes: A Systematic Review , 2020, Sports health.
[38] J. Kennedy,et al. The pharmacogenetics of opioid treatment for pain management , 2020, Journal of psychopharmacology.
[39] X. Zhang,et al. Morphine induces the apoptosis of mouse hippocampal neurons HT-22 through upregulating miR-181-5p. , 2020, European review for medical and pharmacological sciences.
[40] Ling-Ling Chen. The expanding regulatory mechanisms and cellular functions of circular RNAs , 2020, Nature Reviews Molecular Cell Biology.
[41] Elyssa B. Margolis,et al. Differential effects of novel kappa opioid receptor antagonists on dopamine neurons using acute brain slice electrophysiology , 2020, bioRxiv.
[42] Xiaozhou He,et al. δ-Opioid Receptors, microRNAs, and Neuroinflammation in Cerebral Ischemia/Hypoxia , 2020, Frontiers in Immunology.
[43] E. Nestler,et al. Epigenetic Mechanisms of Opioid Addiction , 2020, Biological Psychiatry.
[44] F. Mazzeo,et al. From “sliding” to “winding” filaments theory: A narrative review of mechanisms behind skeletal muscle contraction , 2020, Journal of Human Sport and Exercise - 2020 - Spring Conferences of Sports Science.
[45] R. Lovering,et al. Non-coding RNA regulatory networks. , 2020, Biochimica et biophysica acta. Gene regulatory mechanisms.
[46] S. Lisco,et al. Brain-Derived Extracellular Vesicle microRNA Signatures Associated with In Utero and Postnatal Oxycodone Exposure , 2019, Cells.
[47] K. Solt,et al. The rostromedial tegmental nucleus: a key modulator of pain and opioid analgesia. , 2019, Pain.
[48] Elyssa B. Margolis,et al. Differential Modulation of Ventral Tegmental Area Circuits by the Nociceptin/Orphanin FQ System , 2019, bioRxiv.
[49] F. Mazzeo. Attitude and practice of substance misuse and dietary supplements to improve performance in sport , 2019, Journal of Substance Use.
[50] J. Blendy,et al. Synaptic Regulation by OPRM1 Variants in Reward Neurocircuitry , 2019, The Journal of Neuroscience.
[51] H. Azizi,et al. Adolescent Morphine Exposure in Male Rats Alters the Electrophysiological Properties of Locus Coeruleus Neurons of the Male Offspring , 2019, Neuroscience.
[52] A. Bonci,et al. Dynorphin/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders , 2019, Brain Research.
[53] Mark J. Thomas,et al. Opioid-Mediated Astrocyte–Neuron Signaling in the Nucleus Accumbens , 2019, Cells.
[54] F. Slack,et al. Overexpression of miR-9 in the Nucleus Accumbens Increases Oxycodone Self-Administration , 2019, The international journal of neuropsychopharmacology.
[55] Shuibo Gao,et al. Long non-coding RNA MEG3 attends to morphine-mediated autophagy of HT22 cells through modulating ERK pathway , 2019, Pharmaceutical biology.
[56] Ana Kozomara,et al. miRBase: from microRNA sequences to function , 2018, Nucleic Acids Res..
[57] F. Mazzeo,et al. Use and attitudes toward dietary supplements and drugs amongst Italian elite athletes and its correlation with banned doping substances , 2019, Journal of Human Sport and Exercise - 2019 - Spring Conferences of Sports Science.
[58] S. Novello,et al. NOP Receptor Ligands and Parkinson's Disease. , 2019, Handbook of experimental pharmacology.
[59] L. Kapural,et al. Influence of postoperative analgesia on systemic inflammatory response and postoperative cognitive dysfunction after femoral fractures surgery: a randomized controlled trial , 2018, Regional Anesthesia & Pain Medicine.
[60] Jun-Xu Li,et al. Drug addiction: a curable mental disorder? , 2018, Acta Pharmacologica Sinica.
[61] E. Boyer,et al. Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity , 2018, Journal of Medical Toxicology.
[62] Morphine , 2018, Reactions Weekly.
[63] F. Mazzeo. Anabolic Steroid use in Sports and in Physical Activity: Overview and Analysis , 2018, Sport Mont.
[64] S. A. Fazeli,et al. Potential of Extracellular Vesicles in Neurodegenerative Diseases: Diagnostic and Therapeutic Indications , 2018, Journal of Molecular Neuroscience.
[65] D. W. Odell. Epigenetics of pain mediators , 2018, Current opinion in anaesthesiology.
[66] R. Barkin,et al. Opioid Therapy in Acute and Chronic Pain , 2018, Journal of clinical pharmacology.
[67] Michael R Bruchas,et al. Endogenous and Exogenous Opioids in Pain. , 2018, Annual review of neuroscience.
[68] J. Berke. What does dopamine mean? , 2018, Nature Neuroscience.
[69] K. Muthusamy,et al. A Review of the Pedunculopontine Nucleus in Parkinson's Disease , 2018, Front. Aging Neurosci..
[70] John T. Williams,et al. The Evolving Understanding of Dopamine Neurons in the Substantia Nigra and Ventral Tegmental Area. , 2018, Annual review of physiology.
[71] N. Volkow,et al. Use and Misuse of Opioids in Chronic Pain. , 2018, Annual review of medicine.
[72] P. Rao,et al. Potential Role of Extracellular Vesicles in the Pathophysiology of Drug Addiction , 2018, Molecular Neurobiology.
[73] D. Sanabria,et al. Analgesics and Sport Performance: Beyond the Pain‐Modulating Effects , 2018, PM & R : the journal of injury, function, and rehabilitation.
[74] Elyssa B. Margolis,et al. Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor , 2017, Neuropharmacology.
[75] Aniwaa Owusu Obeng,et al. Review of Opioid Pharmacogenetics and Considerations for Pain Management , 2017, Pharmacotherapy.
[76] F. Bellivier,et al. Pharmacoepigenomics of opiates and methadone maintenance treatment: current data and perspectives. , 2017, Pharmacogenomics.
[77] A. Pipe,et al. A painful dilemma? Analgesic use in sport and the role of anti-doping , 2017, British Journal of Sports Medicine.
[78] Costanza Emanueli,et al. Transcriptional and Post-transcriptional Gene Regulation by Long Non-coding RNA , 2017, Genom. Proteom. Bioinform..
[79] N. Jeske,et al. Identification of a signaling cascade that maintains constitutive δ-opioid receptor incompetence in peripheral sensory neurons , 2017, The Journal of Biological Chemistry.
[80] Tian Liu,et al. Circles reshaping the RNA world: from waste to treasure , 2017, Molecular Cancer.
[81] S. Phillips,et al. Parenteral opioid analgesia: Does it still have a role? , 2017, Best practice & research. Clinical anaesthesiology.
[82] S. Borgland,et al. Projection-Target-Defined Effects of Orexin and Dynorphin on VTA Dopamine Neurons. , 2017, Cell reports.
[83] N. Mercuri,et al. Functional alterations of the dopaminergic and glutamatergic systems in spontaneous α-synuclein overexpressing rats , 2017, Experimental Neurology.
[84] Xing Liu,et al. MiR-218 targets MeCP2 and inhibits heroin seeking behavior , 2017, Scientific Reports.
[85] N. Mercuri,et al. On the properties of identified dopaminergic neurons in the mouse substantia nigra and ventral tegmental area , 2017, The European journal of neuroscience.
[86] J. Paice,et al. Pain and Opioids in Cancer Care: Benefits, Risks, and Alternatives. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[87] Anchal Vishnoi,et al. MiRNA Biogenesis and Regulation of Diseases: An Overview. , 2017, Methods in molecular biology.
[88] G. Koob. Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction , 2017, Psychopharmacology.
[89] Yang In Kim,et al. The contribution of activated peripheral kappa opioid receptors (kORs) in the inflamed knee joint to anti-nociception , 2016, Brain Research.
[90] A. Akopian,et al. GRK2 Constitutively Governs Peripheral Delta Opioid Receptor Activity. , 2016, Cell reports.
[91] Heh-In Im,et al. Brain Reward Circuits in Morphine Addiction , 2016, Molecules and cells.
[92] Canan Kuscu,et al. Biogenesis and Function of Transfer RNA-Related Fragments (tRFs). , 2016, Trends in biochemical sciences.
[93] M. von Zastrow,et al. Molecular Pharmacology of δ-Opioid Receptors , 2016, Pharmacological Reviews.
[94] L. Varriale,et al. Dietary Supplements Use in Competitive and Non-Competitive Boxer: An Exploratory Study , 2016 .
[95] M. Monda,et al. Doping in Italy: An Analysis of its Spread in Ten Years , 2016 .
[96] M. Kretz,et al. Non-coding RNAs: Classification, Biology and Functioning. , 2016, Advances in experimental medicine and biology.
[97] P. Zheng,et al. Morphine disinhibits glutamatergic input to VTA dopamine neurons and promotes dopamine neuron excitation , 2015, eLife.
[98] A. Arnsten,et al. Dopamine’s Actions in Primate Prefrontal Cortex: Challenges for Treating Cognitive Disorders , 2015, Pharmacological Reviews.
[99] A. Bonci,et al. Role of Dopamine Neurons in Reward and Aversion: A Synaptic Plasticity Perspective , 2015, Neuron.
[100] S. Bartlett,et al. The role of δ‐opioid receptors in learning and memory underlying the development of addiction , 2015, British journal of pharmacology.
[101] R. Dubner,et al. Epigenetic regulation of persistent pain. , 2015, Translational research : the journal of laboratory and clinical medicine.
[102] H. Loh,et al. Effects of addictive drugs on adult neural stem/progenitor cells , 2015, Cellular and Molecular Life Sciences.
[103] H. Loh,et al. Morphine Modulates Mouse Hippocampal Progenitor Cell Lineages by Upregulating miR‐181a Level , 2014, Stem cells.
[104] Elyssa B. Margolis,et al. Direct Bidirectional μ-Opioid Control of Midbrain Dopamine Neurons , 2014, The Journal of Neuroscience.
[105] C. Cahill,et al. Does the kappa opioid receptor system contribute to pain aversion? , 2014, Front. Pharmacol..
[106] J. Galligan,et al. Molecular Physiology of Enteric Opioid Receptors , 2014, American journal of gastroenterology supplements.
[107] G. Franklin. Opioids for chronic noncancer pain , 2014, Neurology.
[108] S. Hentges,et al. Separate GABA Afferents to Dopamine Neurons Mediate Acute Action of Opioids, Development of Tolerance, and Expression of Withdrawal , 2014, Neuron.
[109] S. Lammel,et al. Reward and aversion in a heterogeneous midbrain dopamine system , 2014, Neuropharmacology.
[110] K. Befort,et al. 15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse , 2014, Neuropharmacology.
[111] B. Cox. Recent Developments in the Study of Opioid Receptors , 2013, Molecular Pharmacology.
[112] R. Dannals. Positron emission tomography radioligands for the opioid system. , 2013, Journal of labelled compounds & radiopharmaceuticals.
[113] H. Loh,et al. Stress-induced epigenetic regulation of κ-opioid receptor gene involves transcription factor c-Myc , 2012, Proceedings of the National Academy of Sciences.
[114] Borja Mugabure Bujedo,et al. A review of epidural and intrathecal opioids used in the management of postoperative pain. , 2012, Journal of opioid management.
[115] M. Pistis,et al. Inhibitory Inputs from Rostromedial Tegmental Neurons Regulate Spontaneous Activity of Midbrain Dopamine Cells and Their Responses to Drugs of Abuse , 2012, Neuropsychopharmacology.
[116] Barbara A. Sorg,et al. Reconsolidation of drug memories , 2012, Neuroscience & Biobehavioral Reviews.
[117] C. Waddington,et al. REPRINTS AND REFLECTIONS , 2012 .
[118] John T. Williams,et al. Opioid-Sensitive GABA Inputs from Rostromedial Tegmental Nucleus Synapse onto Midbrain Dopamine Neurons , 2011, The Journal of Neuroscience.
[119] P. Haouzi,et al. The "other" respiratory effect of opioids: suppression of spontaneous augmented ("sigh") breaths. , 2011, Journal of applied physiology.
[120] H. Schwarzenbach. Impact of physical activity and doping on epigenetic gene regulation. , 2011, Drug testing and analysis.
[121] G. Calo’,et al. Nociceptin modulates bronchoconstriction induced by sensory nerve activation in mouse lung. , 2009, American journal of respiratory cell and molecular biology.
[122] N. Mercuri,et al. Substantia nigra control of basal ganglia nuclei. , 2009, Journal of neural transmission. Supplementum.
[123] C. Stevens. The evolution of vertebrate opioid receptors. , 2009, Frontiers in bioscience.
[124] Jennifer M. Mitchell,et al. δ-Opioid Receptor Expression in the Ventral Tegmental Area Protects Against Elevated Alcohol Consumption , 2008, The Journal of Neuroscience.
[125] Görel Sundström,et al. Evolution of vertebrate opioid receptors , 2008, Proceedings of the National Academy of Sciences.
[126] J. Ballantyne,et al. Efficacy of Opioids for Chronic Pain: A Review of the Evidence , 2008, The Clinical journal of pain.
[127] Howard S. Smith,et al. Variations in opioid responsiveness. , 2008, Pain physician.
[128] H. Loh,et al. Epigenetic regulation of kappa opioid receptor gene in neuronal differentiation , 2008, Neuroscience.
[129] R. Ransohoff,et al. Multiple roles of chemokine CXCL12 in the central nervous system: A migration from immunology to neurobiology , 2008, Progress in Neurobiology.
[130] S. Datta,et al. Opioid pharmacology. , 2008, Pain physician.
[131] B. Bean. The action potential in mammalian central neurons , 2007, Nature Reviews Neuroscience.
[132] John T. Williams,et al. Kappa opioid inhibition of somatodendritic dopamine inhibitory postsynaptic currents. , 2007, Journal of neurophysiology.
[133] John T. Williams,et al. Properties and Opioid Inhibition of Mesolimbic Dopamine Neurons Vary according to Target Location , 2006, The Journal of Neuroscience.
[134] Elyssa B. Margolis,et al. Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[135] F. Mazzeo,et al. Naltrexone plus benzodiazepine aids abstinence in opioid-dependent patients. , 2005, Life Science.
[136] S. Norn,et al. [History of opium poppy and morphine]. , 2005, Dansk medicinhistorisk arbog.
[137] D. Grandy,et al. Vesicular Dopamine Release Elicits an Inhibitory Postsynaptic Current in Midbrain Dopamine Neurons , 2004, Neuron.
[138] R. Wise. Dopamine, learning and motivation , 2004, Nature Reviews Neuroscience.
[139] Elyssa B. Margolis,et al. κ-Opioid Agonists Directly Inhibit Midbrain Dopaminergic Neurons , 2003, The Journal of Neuroscience.
[140] M. Iacobelli,et al. Use of naltrexone for the treatment of opiate addiction in Campania, Italy: the role of family , 2003 .
[141] C. Brullo,et al. 2-aryl-3-phenylamino-4,5-dihydro-2h-benz[g]indazoles with analgesic activity. , 2003, Farmaco.
[142] D. Zochodne,et al. μ Opioid receptors and analgesia at the site of a peripheral nerve injury , 2003 .
[143] Steven W. Johnson,et al. Actions of orphanin FQ/nociceptin on rat ventral tegmental area neurons in vitro , 2002, British journal of pharmacology.
[144] H. Akil,et al. Nociceptin/orphanin FQ and opioid receptor‐like receptor mRNA expression in dopamine systems , 2002, The Journal of comparative neurology.
[145] N. Mercuri,et al. Intrinsic membrane properties and synaptic inputs regulating the firing activity of the dopamine neurons , 2002, Behavioural Brain Research.
[146] E. Hoffman,et al. Associations between MeCP2 mutations, X-chromosome inactivation, and phenotype. , 2002, Mental retardation and developmental disabilities research reviews.
[147] R. Przewłocki,et al. Opioids in chronic pain. , 2001, European journal of pharmacology.
[148] A. Filippelli,et al. Over-the-counter oral nonsteroidal anti-inflammatory drugs: A pharmacoepidemiologic study in southern Italy , 2001, Advances in therapy.
[149] J T Williams,et al. Cellular and synaptic adaptations mediating opioid dependence. , 2001, Physiological reviews.
[150] Cristina Tassorelli,et al. Functional changes of the basal ganglia circuitry in Parkinson's disease , 2000, Progress in Neurobiology.
[151] Peter A. Smith,et al. Cellular neurophysiological actions of nociceptin/orphanin FQ , 2000, Peptides.
[152] R. Malenka,et al. Properties and Plasticity of Excitatory Synapses on Dopaminergic and GABAergic Cells in the Ventral Tegmental Area , 1999, The Journal of Neuroscience.
[153] S. Watson,et al. Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat , 1999, The Journal of comparative neurology.
[154] B Sakmann,et al. Effect of changes in action potential shape on calcium currents and transmitter release in a calyx-type synapse of the rat auditory brainstem. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[155] R. Clark,et al. Midazolam: a review of therapeutic uses and toxicity. , 1997, The Journal of emergency medicine.
[156] S. Cragg,et al. Characteristics of electrically evoked somatodendritic dopamine release in substantia nigra and ventral tegmental area in vitro. , 1997, Journal of neurophysiology.
[157] J. Williams,et al. A subset of ventral tegmental area neurons is inhibited by dopamine, 5-hydroxytryptamine and opioids , 1997, Neuroscience.
[158] T. Yaksh,et al. Peripheral and Spinal Actions of Opioids in the Blockade of the Autonomic Response Evoked by Compression of the Inflamed Knee Joint , 1996, Anesthesiology.
[159] R. Wise,et al. The neurobiology of addiction , 2019, Annals of the New York Academy of Sciences.
[160] Y. Nakajima,et al. G protein-coupled inward rectifier modulated by dopamine agonists in cultured substantia nigra neurons , 1995, Neuroscience.
[161] H. Matthes,et al. The human delta-opioid receptor: genomic organization, cDNA cloning, functional expression, and distribution in human brain. , 1994, Molecular pharmacology.
[162] G. Bell,et al. Distribution of κ Opioid Receptor mRNA in Adult Mouse Brain: An in Situ Hybridization Histochemistry Study , 1994, Molecular and Cellular Neuroscience.
[163] G Vassart,et al. ORL1, a novel member of the opioid receptor family , 1994, FEBS letters.
[164] A Goldstein,et al. Cloning and pharmacological characterization of a rat kappa opioid receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[165] R. North,et al. Two types of neurone in the rat ventral tegmental area and their synaptic inputs. , 1992, The Journal of physiology.
[166] G. Koob. Drugs of abuse: anatomy, pharmacology and function of reward pathways. , 1992, Trends in pharmacological sciences.
[167] J. Tepper,et al. Stimulus-evoked changes in neostriatal dopamine levels in awake and anesthetized rats as measured by microdialysis , 1991, Brain Research.
[168] F. Foldes. Pain control with intrathecally and peridurally administered opioids and other drugs. , 1991, Anaesthesiologie und Reanimation.
[169] L. Buéno,et al. 7 Action of opiates on gastrointestinal function , 1988 .
[170] J. Culpepper-Morgan,et al. Orally administered kappa as well as mu opiate agonists delay gastrointestinal transit time in the guinea pig. , 1988, Life sciences.
[171] V. Hruby,et al. Peptide opioid antagonist separates peripheral and central opioid antitransit effects. , 1987, The Journal of pharmacology and experimental therapeutics.
[172] N. Mercuri,et al. Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta. , 1987, The Journal of physiology.
[173] J Sawynok,et al. The therapeutic use of heroin: a review of the pharmacological literature. , 1986, Canadian journal of physiology and pharmacology.
[174] J. Fallon,et al. Dynorphin-containing pathways in the substantia nigra and ventral tegmentum: A double labeling study using combined immunofluorescence and retrograde tracing , 1985, Neuropeptides.
[175] M. Palkovits,et al. Distribution of immunoreactive dynorphin in the central nervous system of the rat , 1983, Brain Research.
[176] T. Hökfelt,et al. Immunohistochemical evidence for a dynorphin immunoreactive striato-nigral pathway. , 1982, European journal of pharmacology.
[177] A. Herz,et al. Immunoreactive dynorphin in human brain and pituitary , 1982, Brain Research.
[178] A. Sawa,et al. Evidence that dynorphin-(1–13) acts as an agonist on opioid κ-receptors , 1982 .
[179] C. Chavkin,et al. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. , 1982, Science.
[180] Robert S. Lockhart,et al. Learning and Motivation , 1981 .
[181] L. Hood,et al. Dynorphin-(1-13), an extraordinarily potent opioid peptide. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[182] K. Kangawa,et al. alpha-Neo-endorphin : a "big" Leu-enkephalin with potent opiate activity from porcine hypothalami. , 1979, Biochemical and biophysical research communications.
[183] T. Jessell,et al. Release of dopamine from dendrites in rat substantia nigra , 1976, Nature.
[184] O. Lindvall,et al. Dopamine in dendrites of substantia nigra neurons: suggestions for a role in dendritic terminals , 1975, Brain Research.